The ETFS CURE ETF provides investors with exposure to the US biotechnology sub-industry within the health care sector. CURE adopts an equally weighted strategy, which allocates greater exposure to small and mid-cap shares compared to a market capitalisation weighted approach.
The CURE ETF invests in biotechnology stocks trading on major US exchanges. CURE tracks the performance of the S&P Biotechnology Select Industry Index by holding all of the shares that make up the index, closely in proportion to their index weights. These companies are classified as belonging to the GICS biotechnology sub-industry, and must meet certain market capitalisation and liquidity requirements.
CURE could be used by investors to get tactical exposure to a basket of companies within the USA’s biotechnology industry. Most biotech companies are heavily research-focused and their success can often depend on one breakthrough or regulatory approval, making it a speculative industry.
The following warnings are applied by our team, based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.
This brilliant (and free!) report is issued by Best ETFs Australia, a division of The Rask Group Pty Ltd. It is not a recommendation.
Speak to a financial professional before relying on this information and please read our Financial Services Guide (FSG).
We care about your experience, please let us know if you have any suggestions to improve our site.